The role of α-synuclein in Parkinson's disease: insights from animal models (original) (raw)

• Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047 (1997). The first report showing that a missense mutation in the α-synuclein gene (A53T) causes an early-onset, familial form of PD. This was the first study to identify a genetic cause of PD.
  Article CAS PubMed Google Scholar
• Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608 (1998).
  Article CAS PubMed Google Scholar
• Leroy, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451–452 (1998).
  Article CAS PubMed Google Scholar
• Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256–259 (2003).
  Article CAS PubMed Google Scholar
• Mouradian, M. M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58, 179–185 (2002).
  Article PubMed Google Scholar
• Shimura, H. et al. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263–269 (2001).
  Article CAS PubMed Google Scholar
• Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z. & Lansbury, P. T. Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209–218 (2002).
  Article CAS PubMed Google Scholar
• Miller, D. W. et al. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin–proteasome system. J. Biol. Chem. 2003 Jul 8 (DOI: 10.1074/jbc.M304272200).
• Mitsumoto, A. & Nakagawa, Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic. Res. 35, 885–893 (2001).
  Article CAS PubMed Google Scholar
• Mitsumoto, A. et al. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic. Res. 35, 301–310 (2001).
  Article CAS PubMed Google Scholar
• Wilson, M. A., Collins, J. L., Hod, Y., Ringe, D. & Petsko, G. A. The 1.1-Å resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc. Natl Acad. Sci. USA 100, 9256–9261 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997). The first study to demonstrate the presence of α-synuclein in the Lewy bodies and Lewy neurites of patients with idiopathic PD and Lewy body dementia.
  Article CAS PubMed Google Scholar
• Wakabayashi, K. et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47, 521–523 (2000).
  Article CAS PubMed Google Scholar
• Schlossmacher, M. G. et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160, 1655–1667 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Kawamoto, Y. et al. 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J. Neuropathol. Exp. Neurol. 61, 245–253 (2002).
  Article CAS PubMed Google Scholar
• Yamazaki, M. et al. α-Synuclein inclusions in amygdala in the brains of patients with the parkinsonism–dementia complex of Guam. J. Neuropathol. Exp. Neurol. 59, 585–591 (2000).
  Article CAS PubMed Google Scholar
• Baba, M. et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884 (1998).
  CAS PubMed PubMed Central Google Scholar
• Gai, W. P. et al. α-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. Exp. Neurol. 181, 68–78 (2003).
  Article CAS PubMed Google Scholar
• Conway, K. A., Harper, J. D. & Lansbury, P. T. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nature Med. 4, 1318–1320 (1998). This work described the formation of α-synuclein protofibrils and fibrils during the process of fibrillization. A53T α-synuclein mutant protein was shown to fibrillize faster than wild-type protein.
  Article CAS PubMed Google Scholar
• Wood, S. J. et al. α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509–19512 (1999).
  Article CAS PubMed Google Scholar
• El-Agnaf, O. M. et al. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS Lett. 440, 71–75 (1998).
  Article CAS PubMed Google Scholar
• Giasson, B. I. & Lee, V. M. Parkin and the molecular pathways of Parkinson's disease. Neuron 31, 885–888 (2001).
  Article CAS PubMed Google Scholar
• Conway, K. A. et al. Accelerated oligomerization by Parkinson's disease linked α-synuclein mutants. Ann. NY Acad. Sci. 920, 42–45 (2000).
  Article CAS PubMed Google Scholar
• Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571–576 (2000). This seminal study indicated that both α-synuclein mutations responsible for familial PD increase the rate of protofibril formation during the process of fibrillization.
  Article CAS PubMed PubMed Central Google Scholar
• Volles, M. J. & Lansbury, P. T. Jr. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595–4602 (2002). This paper demonstrated that α-synuclein protofibrils can permeabilize vesicles in vitro , leading to the release of small cytoplasmic molecules such as DA.
  Article CAS PubMed Google Scholar
• Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. & Lansbury, P. T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002).
  Article CAS PubMed Google Scholar
• Xu, J. et al. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nature Med. 8, 600–606 (2002).
  Article CAS PubMed Google Scholar
• Lo Bianco, C., Ridet, J. L., Schneider, B. L., Deglon, N. & Aebischer, P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl Acad. Sci. USA 99, 10813–10818 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ostrerova-Golts, N. et al. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048–6054 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, K. S. et al. The ceruloplasmin and hydrogen peroxide system induces α-synuclein aggregation in vitro. Biochimie 84, 625–631 (2002).
  Article CAS PubMed Google Scholar
• Junn, E. & Mouradian, M. M. Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320, 146–150 (2002).
  Article CAS PubMed Google Scholar
• Tabner, B. J., Turnbull, S., El-Agnaf, O. M. & Allsop, D. Formation of hydrogen peroxide and hydroxyl radicals from A(β) and α-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic. Biol. Med. 32, 1076–1083 (2002).
  Article CAS PubMed Google Scholar
• George, J. M., Jin, H., Woods, W. S. & Clayton, D. F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361–372 (1995).
  Article CAS PubMed Google Scholar
• Quilty, M. C., Gai, W. P., Pountney, D. L., West, A. K. & Vickers, J. C. Localization of α-, β-, and γ-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma. Exp. Neurol. 182, 195–207 (2003).
  Article CAS PubMed Google Scholar
• Abeliovich, A. et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239–252 (2000). The first study to create α-synuclein-knockout mice, showing that α-synuclein deletion only led to slight changes in synaptic transmission.
  Article CAS PubMed Google Scholar
• Cabin, D. E. et al. Synaptic vesicle depletion with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J. Neurosci. 22, 8797–8807 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Perez, R. G. et al. A role for α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090–3099 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Dauer, W. et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl Acad. Sci. USA 99, 14524–14529 (2002). These authors were the first to show that α-synuclein- knockout mice, and neuronal cultures derived from these mice, are resistant to the neurotoxin MPTP.
  Article CAS PubMed PubMed Central Google Scholar
• Schluter, O. M. et al. Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 118, 985–1002 (2003).
  Article CAS PubMed Google Scholar
• Fearnley, J. M. & Lees, A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283–2301 (1991).
  Article PubMed Google Scholar
• Marsden, C. D. Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol. 17, S32–S44 (1994).
  Article PubMed Google Scholar
• Dawson, T. M. & Dawson, V. L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nature Neurosci. 5, S1058–S1061 (2002).
  Article CAS Google Scholar
• Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979–980 (1983).
  Article CAS PubMed Google Scholar
• Cardellach, F. et al. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 43, 2258–2262 (1993).
  Article CAS PubMed Google Scholar
• Blin, O. et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J. Neurol. Sci. 125, 95–101 (1994).
  Article CAS PubMed Google Scholar
• Owen, A. D., Schapira, A. H., Jenner, P. & Marsden, C. D. Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. J. Neural Transm. Suppl. 51, 167–173 (1997).
  Article CAS PubMed Google Scholar
• Liu, Y., Fiskum, G. & Schubert, D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80, 780–787 (2002).
  Article CAS PubMed Google Scholar
• Kang, J. H. & Kim, K. S. Enhanced oligomerization of the α-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Mol. Cells 15, 87–93 (2003).
  CAS PubMed Google Scholar
• Forno, L. S., DeLanney, L. E., Irwin, I. & Langston, J. W. Electron microscopy of Lewy bodies in the amygdala–parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey. Adv. Neurol. 69, 217–228 (1996).
  CAS PubMed Google Scholar
• Spillantini, M. G. et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205–208 (1998).
  Article CAS PubMed Google Scholar
• Kowall, N. W. et al. MPTP induces α-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211–213 (2000).
  Article CAS PubMed Google Scholar
• Vila, M., Wu, D. C. & Przedborski, S. Engineered modeling and the secrets of Parkinson's disease. Trends Neurosci. 24, S49–S55 (2001).
  Article CAS PubMed Google Scholar
• Kuhn, K. et al. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur. J. Neurosci. 17, 1–12 (2003).
  Article PubMed Google Scholar
• Beal, M. F. Experimental models of Parkinson's disease. Nature Rev. Neurosci. 2, 325–334 (2001).
  Article CAS Google Scholar
• Meredith, G. E. et al. Lysosomal malfunction accompanies α-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956, 156–165 (2002).
  Article CAS PubMed Google Scholar
• Neystat, M. et al. α-Synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov. Disord. 14, 417–422 (1999).
  Article CAS PubMed Google Scholar
• Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L. & Richardson, R. J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50, 1346–1350 (1998).
  Article CAS PubMed Google Scholar
• Menegon, A., Board, P. G., Blackburn, A. C., Mellick, G. D. & Le Couteur, D. G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352, 1344–1346 (1998).
  Article CAS PubMed Google Scholar
• Hensley, K. et al. Interaction of α-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J. Neurochem. 71, 2549–2557 (1998).
  Article CAS PubMed Google Scholar
• Seaton, T. A., Cooper, J. M. & Schapira, A. H. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777, 110–118 (1997).
  Article CAS PubMed Google Scholar
• Betarbet, R., Sherer, T. B. & Greenamyre, J. T. Animal models of Parkinson's disease. Bioessays 24, 308–318 (2002).
  Article CAS PubMed Google Scholar
• Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. 3, 1301–1306 (2000). This study described the rotenone rat model of PD. These animals showed nigrostriatal system degeneration, Lewy-like inclusion bodies and motor impairment.
  Article CAS PubMed Google Scholar
• Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265–1269 (2000). These authors were the first to develop α-synuclein transgenic mice. These mice were created using the PDGFβ promoter, and exhibited a loss of striatal dopaminergic terminals.
  Article CAS PubMed Google Scholar
• Auluck, P. K. & Bonini, N. M. Pharmacological prevention of Parkinson disease in Drosophila. Nature Med. 8, 1185–1186 (2002).
  Article CAS PubMed Google Scholar
• Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson's disease. Nature 404, 394–398 (2000). The first published example of α-synuclein Drosophila transgenics. The wild-type and mutant (A53T and A30P) α-synuclein transgenic flies exhibited DA neuron loss and neuronal inclusions resembling Lewy bodies.
  Article CAS PubMed Google Scholar
• Takahashi, M. et al. Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila. Neurosci. Lett. 336, 155–158 (2003).
  Article CAS PubMed Google Scholar
• Pendleton, R. G., Parvez, F., Sayed, M. & Hillman, R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J. Pharmacol. Exp. Ther. 300, 91–96 (2002).
  Article CAS PubMed Google Scholar
• Fujiwara, H. et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biol. 4, 160–164 (2002).
  Article CAS PubMed Google Scholar
• Kahle, P. J. et al. Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 159, 2215–2225 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Warrick, J. M. et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nature Genet. 23, 425–428 (1999).
  Article CAS PubMed Google Scholar
• Bonini, N. M. Chaperoning brain degeneration. Proc. Natl Acad. Sci. USA 99, S16407–S16411 (2002).
  Article CAS Google Scholar
• Yang, Y., Nishimura, I., Imai, Y., Takahashi, R. & Lu, B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37, 911–924 (2003).
  Article CAS PubMed Google Scholar
• Greene, J. C. et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA 100, 4078–4083 (2003). The first deletion of the parkin gene in Drosophila . The parkin-null flies exhibited muscle degeneration but no defects in the dopaminergic system.
  Article CAS PubMed PubMed Central Google Scholar
• Adams, M. D. et al. The genome sequence of Drosophila melanogaster. Science 287, 2185–2195 (2000).
  Article PubMed Google Scholar
• Sturchler-Pierrat, C. et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl Acad. Sci. USA 94, 13287–13292 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Wiessner, C. et al. Neuron-specific transgene expression of Bcl-X L but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice. Neurosci. Lett. 268, 119–122 (1999).
  Article CAS PubMed Google Scholar
• van der Putten, H. et al. Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20, 6021–6029 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Kahle, P. J., Neumann, M., Ozmen, L. & Haass, C. Physiology and pathophysiology of α-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann. NY Acad. Sci. 920, 33–41 (2000).
  Article CAS PubMed Google Scholar
• Matsuoka, Y. et al. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8, 535–539 (2001).
  Article CAS PubMed Google Scholar
• Rathke-Hartlieb, S. et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice. J. Neurochem. 77, 1181–1184 (2001).
  Article CAS PubMed Google Scholar
• Richfield, E. K. et al. Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp. Neurol. 175, 35–48 (2002).
  Article CAS PubMed Google Scholar
• Giasson, B. I. et al. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34, 521–533 (2002).
  Article CAS PubMed Google Scholar
• Lee, M. K. et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 8968–8973 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M. & Masliah, E. β-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213–223 (2001).
  Article CAS PubMed Google Scholar
• Park, J. Y. & Lansbury, P. T. Jr. β-Synuclein inhibits formation of α-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 42, 3696–3700 (2003).
  Article CAS PubMed Google Scholar
• Klein, R. L., King, M. A., Hamby, M. E. & Meyer, E. M. Dopaminergic cell loss induced by human A30P α-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13, 605–612 (2002).
  Article CAS PubMed Google Scholar
• Kirik, D. et al. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780–2791 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Rochet, J. C., Conway, K. A. & Lansbury, P. T. Jr. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α-synuclein. Biochemistry 39, 10619–10626 (2000).
  Article CAS PubMed Google Scholar
• Kirik, D. et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson's disease. Proc. Natl Acad. Sci. USA 100, 2884–2889 (2003). The first study attempting to create a primate model overexpressing the α-synuclein gene. These primates exhibited nigrostriatal degeneration, but lacked a motor phenotype resembling PD.
  Article CAS PubMed PubMed Central Google Scholar
• Uversky, V. N. & Fink, A. L. Amino acid determinants of α-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett. 522, 9–13 (2002).
  Article CAS PubMed Google Scholar
• Couzin, J. Parkinson's disease. Dopamine may sustain toxic protein. Science 294, 1257–1258 (2001).
  Article CAS PubMed Google Scholar
• Hishikawa, N., Hashizume, Y., Yoshida, M. & Sobue, G. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol. (Berl.) 105, 341–350 (2003).
  Google Scholar
• Conway, K. A., Rochet, J. C., Bieganski, R. M. & Lansbury, P. T. Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346–1349 (2001). This prominent work showed that DA stabilizes the protofibrillary conformation of α-synuclein.
  Article CAS PubMed Google Scholar